Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNF-alpha-dependent insulin resistance and endothelial dysfunction in rheumatoid arthritis and metabolic syndrome
2005-000492-18Phase 2Completed
- Sponsor
- Policlinico Gemelli
- Start
- Nov 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of infliximab in rheumatoid arthritis (RA) and cardiometabolic risk (CMR), sponsored by Policlinico Gemelli. Started Nov 2007; status: completed.
02
Drugs
infliximab
03
Conditions
rheumatoid arthritis (RA)cardiometabolic risk (CMR)
Beyond the preview
Go deeper on 2005-000492-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000492-18.